Symbols / TTOO
TTOO Chart
About
T2 Biosystems, Inc. engages in the development and commercialization of medical diagnostic products for critical unmet needs in the healthcare. Its products include T2Dx instrument, T2Candida panel, and T2Bacteria panel. The company was incorporated in 2006 and is based in Lexington, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 11.22K |
| Enterprise Value | 16.87M | Income | -42.95M | Sales | 7.68M |
| Book/sh | -0.62 | Cash/sh | 0.10 | Dividend Yield | — |
| Payout | 0.00% | Employees | 113 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | 0.00 | P/B | -0.00 | P/C | — |
| EV/EBITDA | -0.41 | EV/Sales | 2.20 | Quick Ratio | 0.17 |
| Current Ratio | 0.40 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.03 | EPS next Y | -1.19 | EPS Growth | — |
| Revenue Growth | 34.90% | Earnings | 2025-06-11 16:00 | ROA | -84.85% |
| ROE | — | ROIC | — | Gross Margin | -247.83% |
| Oper. Margin | -5.12% | Profit Margin | 0.00% | Shs Outstand | 28.05M |
| Shs Float | 11.90M | Short Float | 4.87% | Short Ratio | 0.71 |
| Short Interest | — | 52W High | 0.18 | 52W Low | 0.00 |
| Beta | 0.84 | Avg Volume | 53.61K | Volume | 35.00 |
| Target Price | — | Recom | None | Prev Close | $0.01 |
| Price | $0.00 | Change | -92.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-16.92
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-07-30 | main | Canaccord Genuity | Hold → Hold | $5 |
| 2024-04-29 | main | Canaccord Genuity | Hold → Hold | $3 |
- T2 BIOSYSTEMS Earnings Preview: Recent $TTOO Insider Trading, Hedge Fund Activity, and More - Nasdaq Wed, 04 Jun 2025 07
- T2 Biosystems, Inc. Announces Intent to Complete Winding Down of Operations - marketscreener.com Wed, 04 Feb 2026 09
- T2 Biosystems to be delisted from Nasdaq - Investing.com ue, 11 Feb 2025 08
- Do Institutions Own T2 Biosystems, Inc. (NASDAQ:TTOO) Shares? - Yahoo Finance Mon, 10 Jun 2019 07
- TTOO Stock: Why T2 Biosystems Is Shooting Higher Today - InvestorPlace Fri, 05 Feb 2021 08
- TTOO Stock | An Analysis of T2 Biosystems - Nanalyze ue, 22 Aug 2023 16
- TTOO - T2 Biosystems Latest Stock News & Market Updates - Stock Titan hu, 20 Aug 2020 14
- T2 Biosystems, Inc. (TTOO) Stock Review: High Risk, High Reward - StockInvest.us Wed, 02 Aug 2023 07
- SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation - GlobeNewswire Mon, 02 Oct 2023 07
- Why Shares of T2 Biosystems Are Falling Friday - The Motley Fool Fri, 13 Oct 2023 07
- T2 Biosystems stock plunges to 52-week low of $0.55 - Investing.com ue, 12 Nov 2024 08
- T2 Biosystems Inc (TTOO) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance Fri, 11 Oct 2024 07
- What Is Going on With T2 Biosystems (TTOO) Stock Today? - InvestorPlace Fri, 23 Sep 2022 07
- Volatility and Weak Fundamentals Push T2 Biosystems (TTOO) Stock into Risky Territory - StockInvest.us Mon, 16 Oct 2023 18
- T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform - Stock Titan ue, 08 Oct 2024 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 55 | 133.0 | — | Sale at price 2.42 per share. | ELSBREE DAVID B | Director | — | 2024-09-13 00:00:00 | D |
| 1 | 1824800 | nan | — | — | CR GROUP, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-05-09 00:00:00 | I |
| 2 | 4748335 | — | — | Stock Award(Grant) at price 0.00 per share. | CR GROUP, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-05-03 00:00:00 | I |
| 3 | 3280618 | — | — | Stock Award(Grant) at price 0.00 per share. | CR GROUP, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-04-12 00:00:00 | I |
Financials
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -46.79M | -53.96M | -40.12M |
| TotalUnusualItems | 2.91M | -913.00K | 1.01M |
| TotalUnusualItemsExcludingGoodwill | 2.91M | -913.00K | 1.01M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -50.08M | -62.00M | -49.24M |
| ReconciledDepreciation | 859.00K | 1.05M | 2.54M |
| ReconciledCostOfRevenue | 15.36M | 21.01M | 20.70M |
| EBITDA | -43.88M | -54.87M | -39.11M |
| EBIT | -44.73M | -55.92M | -41.65M |
| NetInterestIncome | -5.34M | -6.08M | -7.48M |
| InterestExpense | 5.34M | 6.08M | 7.60M |
| InterestIncome | 8.00K | 112.00K | |
| NormalizedIncome | -52.99M | -61.09M | -50.25M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -50.08M | -62.00M | -49.24M |
| TotalExpenses | 54.35M | 77.35M | 71.03M |
| TotalOperatingIncomeAsReported | -49.66M | -55.20M | -42.97M |
| DilutedAverageShares | 2.61M | 51.00K | 1.59M |
| BasicAverageShares | 2.61M | 51.00K | 1.59M |
| DilutedEPS | -19.19 | -1.23K | -31.00 |
| BasicEPS | -19.19 | -1.23K | -31.00 |
| DilutedNIAvailtoComStockholders | -50.08M | -62.33M | -49.24M |
| NetIncomeCommonStockholders | -50.08M | -62.33M | -49.24M |
| PreferredStockDividends | 330.00K | ||
| NetIncome | -50.08M | -62.00M | -49.24M |
| NetIncomeIncludingNoncontrollingInterests | -50.08M | -62.00M | -49.24M |
| NetIncomeContinuousOperations | -50.08M | -62.00M | -49.24M |
| PretaxIncome | -50.08M | -62.00M | -49.24M |
| OtherIncomeExpense | 2.42M | -874.00K | 1.22M |
| OtherNonOperatingIncomeExpenses | -495.00K | 39.00K | 206.00K |
| SpecialIncomeCharges | -2.51M | -151.00K | |
| ImpairmentOfCapitalAssets | 2.51M | 151.00K | |
| GainOnSaleOfSecurity | 5.42M | -762.00K | 1.01M |
| NetNonOperatingInterestIncomeExpense | -5.34M | -6.08M | -7.48M |
| InterestExpenseNonOperating | 5.34M | 6.08M | 7.60M |
| InterestIncomeNonOperating | 8.00K | 112.00K | |
| OperatingIncome | -47.15M | -55.05M | -42.97M |
| OperatingExpense | 38.98M | 56.34M | 50.33M |
| ResearchAndDevelopment | 14.15M | 25.71M | 21.80M |
| SellingGeneralAndAdministration | 24.83M | 30.62M | 28.53M |
| GrossProfit | -8.17M | 1.29M | 7.36M |
| CostOfRevenue | 15.36M | 21.01M | 20.70M |
| TotalRevenue | 7.19M | 22.30M | 28.06M |
| OperatingRevenue | 7.19M | 22.30M | 28.06M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| OrdinarySharesNumber | 4.06M | 77.17K | 1.66M |
| ShareIssued | 4.06M | 77.17K | 1.66M |
| NetDebt | 25.59M | 39.32M | 25.55M |
| TotalDebt | 49.50M | 59.22M | 58.32M |
| TangibleBookValue | -28.04M | -39.66M | -12.90M |
| InvestedCapital | 13.25M | 10.00M | 34.89M |
| WorkingCapital | -30.96M | 9.23M | 32.71M |
| NetTangibleAssets | -28.04M | -39.66M | -12.90M |
| CapitalLeaseObligations | 8.21M | 9.57M | 10.53M |
| CommonStockEquity | -28.04M | -39.66M | -12.90M |
| TotalCapitalization | -28.04M | 10.00M | 34.89M |
| TotalEquityGrossMinorityInterest | -28.04M | -39.66M | -12.90M |
| StockholdersEquity | -28.04M | -39.66M | -12.90M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -4.00K | |
| RetainedEarnings | -584.30M | -534.22M | -472.22M |
| AdditionalPaidInCapital | 556.26M | 494.56M | 459.31M |
| CapitalStock | 4.00K | 0.00 | 3.00K |
| CommonStock | 4.00K | 0.00 | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 62.83M | 73.98M | 73.44M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 6.68M | 63.85M | 61.75M |
| OtherNonCurrentLiabilities | 4.85M | 4.58M | |
| DerivativeProductLiabilities | 0.00 | 1.09M | 0.00 |
| NonCurrentAccruedExpenses | 0.00 | 4.85M | |
| NonCurrentDeferredLiabilities | 83.00K | 52.00K | 28.00K |
| NonCurrentDeferredRevenue | 83.00K | 52.00K | 28.00K |
| LongTermDebtAndCapitalLeaseObligation | 6.60M | 57.87M | 57.15M |
| LongTermCapitalLeaseObligation | 6.60M | 8.21M | 9.36M |
| LongTermDebt | 49.65M | 47.79M | |
| CurrentLiabilities | 56.15M | 10.13M | 11.69M |
| OtherCurrentLiabilities | 1.79M | 39.00K | |
| CurrentDeferredLiabilities | 224.00K | 172.00K | 518.00K |
| CurrentDeferredRevenue | 224.00K | 172.00K | 518.00K |
| CurrentDebtAndCapitalLeaseObligation | 42.90M | 1.35M | 1.17M |
| CurrentCapitalLeaseObligation | 1.62M | 1.35M | 1.17M |
| CurrentDebt | 41.28M | ||
| OtherCurrentBorrowings | 41.28M | ||
| PayablesAndAccruedExpenses | 11.24M | 8.56M | 10.00M |
| CurrentAccruedExpenses | 9.71M | 7.27M | 7.16M |
| InterestPayable | 839.00K | 1.01M | 974.00K |
| Payables | 1.53M | 1.30M | 2.83M |
| AccountsPayable | 1.53M | 1.30M | 2.83M |
| TotalAssets | 34.80M | 34.33M | 60.54M |
| TotalNonCurrentAssets | 9.61M | 14.97M | 16.14M |
| OtherNonCurrentAssets | 555.00K | 1.69M | 1.70M |
| InvestmentsAndAdvances | 0.00 | ||
| InvestmentinFinancialAssets | 0.00 | ||
| NetPPE | 9.05M | 13.27M | 14.44M |
| AccumulatedDepreciation | -14.85M | -14.26M | -14.98M |
| GrossPPE | 23.90M | 27.53M | 29.42M |
| Leases | 3.61M | 3.78M | 3.77M |
| ConstructionInProgress | 23.00K | 685.00K | 512.00K |
| OtherProperties | 18.59M | 21.32M | 23.41M |
| MachineryFurnitureEquipment | 1.69M | 1.74M | 1.73M |
| Properties | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 25.19M | 19.36M | 44.39M |
| OtherCurrentAssets | 3.26M | 2.58M | 3.11M |
| PrepaidAssets | 3.11M | ||
| Inventory | 4.82M | 4.29M | 3.91M |
| FinishedGoods | 1.50M | 1.10M | 1.36M |
| WorkInProcess | 1.44M | 1.18M | 953.00K |
| RawMaterials | 1.88M | 2.00M | 1.59M |
| Receivables | 1.42M | 2.16M | 5.13M |
| AccountsReceivable | 1.42M | 2.16M | 5.13M |
| AllowanceForDoubtfulAccountsReceivable | -100.00K | -100.00K | |
| GrossAccountsReceivable | 1.52M | 2.26M | 5.13M |
| CashCashEquivalentsAndShortTermInvestments | 15.69M | 10.33M | 32.24M |
| OtherShortTermInvestments | 0.00 | 10.00M | |
| CashAndCashEquivalents | 15.69M | 10.33M | 22.25M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| FreeCashFlow | -48.33M | -50.97M | -39.33M |
| RepurchaseOfCapitalStock | 0.00 | -330.00K | 0.00 |
| IssuanceOfCapitalStock | 52.73M | 29.46M | 19.97M |
| CapitalExpenditure | -192.00K | -339.00K | -460.00K |
| InterestPaidSupplementalData | 3.86M | 3.92M | 3.81M |
| EndCashPosition | 16.24M | 11.88M | 23.80M |
| BeginningCashPosition | 11.88M | 23.80M | 17.34M |
| ChangesInCash | 4.36M | -11.92M | 6.45M |
| FinancingCashFlow | 52.69M | 29.05M | 20.54M |
| CashFlowFromContinuingFinancingActivities | 52.69M | 29.05M | 20.54M |
| NetOtherFinancingCharges | -62.00K | -243.00K | |
| ProceedsFromStockOptionExercised | 19.00K | 165.00K | 567.00K |
| NetPreferredStockIssuance | 0.00 | -30.00K | 0.00 |
| PreferredStockPayments | 0.00 | -330.00K | 0.00 |
| PreferredStockIssuance | 0.00 | 300.00K | 0.00 |
| NetCommonStockIssuance | 52.73M | 29.16M | 19.97M |
| CommonStockIssuance | 52.73M | 29.16M | 19.97M |
| InvestingCashFlow | -192.00K | 9.66M | 24.79M |
| CashFlowFromContinuingInvestingActivities | -192.00K | 9.66M | 24.79M |
| NetInvestmentPurchaseAndSale | 0.00 | 10.00M | 25.25M |
| SaleOfInvestment | 0.00 | 10.00M | 25.25M |
| PurchaseOfInvestment | 0.00 | ||
| NetPPEPurchaseAndSale | -192.00K | -339.00K | -460.00K |
| SaleOfPPE | 0.00 | ||
| PurchaseOfPPE | -192.00K | -339.00K | -460.00K |
| OperatingCashFlow | -48.14M | -50.63M | -38.87M |
| CashFlowFromContinuingOperatingActivities | -48.14M | -50.63M | -38.87M |
| ChangeInWorkingCapital | -4.04M | -503.00K | -2.17M |
| ChangeInOtherWorkingCapital | 83.00K | -322.00K | -108.00K |
| ChangeInOtherCurrentLiabilities | -1.35M | -1.37M | -1.15M |
| ChangeInPayablesAndAccruedExpense | -2.22M | -1.30M | 1.53M |
| ChangeInAccruedExpense | -2.45M | 261.00K | 769.00K |
| ChangeInPayable | 231.00K | -1.57M | 761.00K |
| ChangeInAccountPayable | 231.00K | -1.57M | 761.00K |
| ChangeInPrepaidAssets | -550.00K | 471.00K | -467.00K |
| ChangeInInventory | -744.00K | -949.00K | -1.94M |
| ChangeInReceivables | 743.00K | 2.97M | -35.00K |
| ChangesInAccountReceivables | 743.00K | 2.97M | -35.00K |
| OtherNonCashItems | 3.68M | 3.36M | 3.93M |
| StockBasedCompensation | 4.35M | 6.49M | 7.09M |
| AssetImpairmentCharge | 2.51M | 151.00K | 0.00 |
| DepreciationAmortizationDepletion | 859.00K | 1.05M | 2.54M |
| DepreciationAndAmortization | 859.00K | 1.05M | 2.54M |
| Depreciation | 2.27M | 2.54M | |
| OperatingGainsLosses | -5.42M | 829.00K | -1.02M |
| GainLossOnInvestmentSecurities | -5.42M | 829.00K | -1.02M |
| GainLossOnSaleOfPPE | 3.00K | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -50.08M | -62.00M | -49.24M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for TTOO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|